Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc.
Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. in Plant Molecular Genetics from Seoul National University, and a B.S. in Horticultural Science from Seoul National University.
Dr. Versavel has served as NeuroBo’s Chief Medical Officer since February 2018. Since March 2014, Dr. Versavel has also served as President of vZenium LLC, providing consulting services to life sciences companies engaged in central nervous system clinical development. Before joining NeuroBo, from From March to August 2019, he was Chief Medical Officer of Cavion, Inc., a privately held, clinical stage biotechnology company developing therapeutics for neurological diseases. Dr. Versavel also served as the Chief Medical Officer of Alzheon, Inc., a privately held, clinical-stage biopharmaceutical company focused on Alzheimer’s disease, from September 2013 until September 2015. Dr. Versavel has over 25 years of clinical development experience in neuropathic pain and multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials, and in the support of marketed products in public companies Bayer AG, Schering AG, Parke Davis, Pfizer and Sunovion.
Dr. Versavel earned a M.D. from the University of Antwerp, a Ph.D. in clinical pharmacology from the Humboldt University of Berlin and an M.B.A. from the University of Michigan.
Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials.
Ms. Shannon is a Registered Nurse. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. in Health Sciences Administration from Ottawa University.